RankAlpha logo
Back to Rankings

SRPT

Sarepta TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Sarepta combines positive Q2 operating income, a commercial Duchenne portfolio, upcoming DM1/FSHD data, and potential PMO approval conversions. The $22.087 median target is above the $18.10 anchor price, but the target count is unavailable.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.3.
What can break
AMONDYS 45 and VYONDYS 53 approval conversions are binary regulatory outcomes.
Momentum
86
Value
51
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $28.00 · Bear $12.00Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $22.26
Why
Momentum86 · Δ7d +7.0
Value51 · Δ7d 0.0
Sentiment58 · Δ7d +8.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +8.3.

Contradictions & invalidation

  • • AMONDYS 45 and VYONDYS 53 approval conversions are binary regulatory outcomes.
  • • DM1 and FSHD programs have early biomarker evidence but no established efficacy or durability.
  • • ELEVIDYS weakness, narrowed product guidance, binary regulatory outcomes, and unproven clinical efficacy could keep the stock under pressure.

Catalyst clock

2026-08-17

Q2 profitability offsets mixed commercial signal

Lead driver: Sentiment · See AI snapshot
Momentum
86
9% active weight
Current posture
7d trendImproving
Δ7d
+7.0
Δ21d
+67.4
Value
51
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
58
62% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
-18.9
Why this grade

Composite grade C. Momentum 86.4 / Value 51.4 / Sentiment 58.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method

B+
Bull case
24%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Most likely
B
Base case
52%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
24%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.92B
Beta
0.39
Shares Out
105.63M
P/E (TTM) · Derived
-2.6
P/S (TTM)
0.91
P/FCF (TTM) · Derived
21.15
Rev YoY
-34.3%
EPS YoY
-102.5%
Gross Margin
+56.6%
Op Margin
-3.2%
Net Debt
$99.9M
Current Ratio
4.42
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data